Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Augmentation therapy for alpha(1)-antitrypsin deficiency.

Georges S Juvelekian1, James K Stoller

  • 1Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

Drugs
|August 11, 2004
PubMed
Summary

Alpha-1 Antitrypsin (AAT) deficiency is an under-recognized genetic condition. Intravenous AAT augmentation therapy shows biochemical efficacy and supports slower lung function decline in deficient individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing mentorship/sponsorship opportunities for pulmonary, critical care and sleep fellows through structured alumni engagement.

BMJ leader·2026
Same author

What ancient wisdom and science know about drivers to high performance in organisations.

BMJ leader·2026
Same author

Countermeasures for doctors' leadership handicaps.

BMJ leader·2026
Same author

Implementation and Assessment of a Novel Interprofessional Educational Initiative in the Medical Intensive Care Unit: A Mixed-Methods Evaluation.

ATS scholar·2026
Same author

Alpha-1 antitrypsin deficiency: A persistently underrecognized condition.

Cleveland Clinic journal of medicine·2026
Same author

Matrix metalloproteinases and disease severity among PI*MZ and PI*ZZ individuals in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) cohort.

BMJ open respiratory research·2025

Area of Science:

  • Pulmonology
  • Genetics
  • Pharmacology

Background:

  • Alpha-1 Antitrypsin (AAT) deficiency is a prevalent yet often overlooked genetic disorder.
  • Advances in understanding AAT deficiency's genetics, physiology, and pathophysiology have been significant since its initial description.

Purpose of the Study:

  • To review the current understanding and treatment of Alpha-1 Antitrypsin (AAT) deficiency.
  • To evaluate the efficacy and evidence supporting intravenous AAT augmentation therapy.

Main Methods:

  • Review of existing literature, including observational studies and surveys.
  • Analysis of biochemical efficacy and functional capacity data related to AAT augmentation.

Main Results:

  • Intravenous AAT administration raises serum AAT levels above the protective threshold, preserving protease inhibitor function.

Related Experiment Videos

  • Observational studies indicate slower forced expiratory volume decline in AAT-deficient individuals receiving augmentation therapy, particularly those with moderate airflow obstruction.
  • Evidence suggests potential anti-inflammatory effects and reduced respiratory infections in augmentation therapy recipients.

    • Conclusions:

    • Intravenous AAT augmentation therapy is biochemically effective and shows promise for slowing disease progression in AAT deficiency.
    • Despite the absence of large randomized controlled trials demonstrating definitive clinical efficacy, substantial evidence supports its use.
    • Intravenous AAT augmentation therapy is the sole FDA-approved treatment for AAT deficiency, with ongoing research into novel therapies.